Gline Matthew bought ROIV
September 18, 2025 · Form 4 insider transaction
Gline Matthew bought 3,315 shares of Roivant Sciences Ltd. at $15.07 per share, a transaction worth $50.0K. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 0 days after the transaction.
Direction
Acquired (buy-side)
Shares
3,315
Price
$15.07
Total value
$50.0K
InsiderGline Matthew
RoleOfficer, Director
CompanyRoivant Sciences Ltd. (ROIV)
SecurityCommon Shares
Transaction codeP: Open-market purchase
Transaction dateSeptember 18, 2025
Filing dateSeptember 18, 2025
Shares owned after17,287,081
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range.